Healthcare / Diagnostics & ResearchBSE
$120.65
-5.60 (-4.22%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $40.9M · quality 51.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$840M
P/E
45.0x
↑EV/EBITDA
9.0x
↓ROE
7.7%
↑Gross Margin
83.0%
↑Debt/Equity
1.34
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+10.1%
FCF CAGR
—
FCF margin
-0.7%
FCF / Net income
-0.16x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $460.1M · net income $19.6M · FCF $-3.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $460.1M | $460.1M | $417.8M | $367.0M | $344.4M |
| Net Income | $19.6M | $19.6M | $15.2M | $11.1M | $32.1M |
| EBITDA | $131.0M | $131.0M | $113.0M | $103.8M | $127.1M |
| EPS | — | — | 2.19 | 1.59 | 4.61 |
| Gross Margin | 83.0% | 83.0% | 82.8% | 89.9% | 90.2% |
| Operating Margin | 11.4% | 11.4% | 11.5% | 12.9% | 14.4% |
| Net Margin | 4.3% | 4.3% | 3.6% | 3.0% | 9.3% |
| Balance Sheet | |||||
| Debt/Equity | 1.34 | 1.34 | 1.24 | 1.39 | 1.54 |
| Current Ratio | 0.82 | 0.82 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.1M | $-3.1M | $40.9M | $44.6M | $41.0M |
| Returns | |||||
| ROE | 7.7% | 7.7% | 6.5% | 5.0% | 15.2% |
| Valuation | |||||
| P/E | 45.02 | 45.02 | 54.29 | — | — |
| EV/EBITDA | 9.01 | 9.01 | 9.84 | — | — |
| P/B | 3.29 | 3.29 | 3.50 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 10.1% | 10.1% | 13.9% | 6.5% | — |
| EPS Growth | — | — | 37.7% | -65.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.6%
Start / end P/E
n/dx → n/dx
EPS bridge
2.19 → n/d
Residual
+14.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.